

Jiing-Chyuan Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9243483/publications.pdf>

Version: 2024-02-01

63
papers

1,785
citations

304602

22
h-index

276775

41
g-index

64
all docs

64
docs citations

64
times ranked

2531
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in intestinal microbiota profiling after upper and lower gastrointestinal surgery. Journal of the Chinese Medical Association, 2021, 84, 354-360.	0.6	1
2	Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan. Journal of the Chinese Medical Association, 2021, 84, 580-587.	0.6	6
3	Safety and importance of colonoscopy in nonagenarians. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	0.6	1
4	Comparison of the effect of clarithromycin triple therapy with or without <i>N</i> -acetylcysteine in the eradication of <i>Helicobacter pylori</i> : a randomized controlled trial. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092730.	1.4	5
5	Post endoscopic retrograde cholangiopancreatography cholecystitis: The incidence and risk factors analysis. Journal of the Chinese Medical Association, 2020, 83, 733-736.	0.6	5
6	Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2096-2102.	1.4	1
7	Accuracy of rapid <i>Helicobacter pylori</i> antigen tests for the surveillance of the updated prevalence of <i>H. pylori</i> in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1626-1633.	0.8	13
8	Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. Journal of Clinical Medicine, 2019, 8, 1108.	1.0	5
9	Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after <i>Helicobacter pylori</i> eradication: a multicentre, open-label, randomised trial. Lancet Infectious Diseases, The, 2019, 19, 1109-1120.	4.6	127
10	Effects of Aspirin or Clopidogrel on Colorectal Cancer Chemoprevention in Patients with Type 2 Diabetes Mellitus. Cancers, 2019, 11, 1468.	1.7	9
11	The long term microbiota and metabolic status in patients with colorectal cancer after curative colon surgery. PLoS ONE, 2019, 14, e0218436.	1.1	15
12	Predictors of stent occlusion in patients with unresectable pancreatic cancer after biliary metal stents. Journal of the Chinese Medical Association, 2019, 82, 762-766.	0.6	4
13	Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study. Journal of the Formosan Medical Association, 2019, 118, 939-944.	0.8	29
14	Risk Factors for Upper Gastrointestinal Bleeding in Patients Taking Selective COX-2 Inhibitors: A Nationwide Population-Based Cohort Study. Pain Medicine, 2018, 19, 225-231.	0.9	9
15	Same-day Versus Split-dose Bowel Preparation Before Colonoscopy. Journal of Clinical Gastroenterology, 2018, 52, 392-400.	1.1	34
16	The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy. PLoS ONE, 2018, 13, e0206930.	1.1	19
17	Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory <i>Helicobacter pylori</i> Infection. Gastroenterology, 2018, 155, 1109-1119.	0.6	66
18	The implementation of the consensus on the management of <i>Helicobacter pylori</i> and barriers to consensus. Helicobacter, 2018, 23, e12533.	1.6	2

#	ARTICLE	IF	CITATIONS
19	14-day sequential therapy versus 10-day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of <i>Helicobacter pylori</i> : a multicentre, non-inferiority, randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2510-2518.	1.3	20
20	The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 759-765.	0.6	4
21	Risk factors of the peptic ulcer bleeding in aging uremia patients under regular hemodialysis. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 1027-1032.	0.6	11
22	Metabolic syndrome and gastrointestinal/hepatobiliary diseases. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 3-4.	0.6	7
23	The risk factors and prognostic factors of intrahepatic cholangiocarcinoma. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 121-122.	0.6	4
24	Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1084-1093.	0.2	52
25	Cholecystectomy decreased the recurrent cholangitis after clearance of bile duct stones by ERCP in patients with gallstone-related cholangitis. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 690-696.	0.6	5
26	Cholecystectomy Reduces Recurrent Pancreatitis and Improves Survival After Endoscopic Sphincterotomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 294-301.	0.9	9
27	Chronic obstructive pulmonary disease is associated with increased recurrent peptic ulcer bleeding risk. <i>European Journal of Internal Medicine</i> , 2017, 37, 75-82.	1.0	15
28	Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for <i>Helicobacter pylori</i> eradication: analysis of five randomized trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3481-3489.	1.3	23
29	Fecal immunochemical tests for surveillance of the colorectal neoplasia after polypectomy. <i>Advances in Digestive Medicine</i> , 2017, 4, 119-120.	0.1	0
30	Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trial. <i>Gut</i> , 2016, 65, 1784-1792.	6.1	71
31	Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. <i>European Journal of Internal Medicine</i> , 2016, 32, 91-95.	1.0	30
32	Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2016, 388, 2355-2365.	6.3	128
33	Will saliva test be a good method to detect <i>Helicobacter pylori</i> in <i>H. pylori</i> -infected patients?. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 351-352.	0.6	3
34	Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of <i>Helicobacter pylori</i> : A Randomized Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 381-387.	0.2	43
35	Establishing a risk scoring system for predicting erosive esophagitis. <i>Advances in Digestive Medicine</i> , 2016, 3, 95-100.	0.1	2
36	The benefits and risks of proton pump inhibitor therapy. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 1-2.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 764-772.	0.8	30
38	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. <i>Oncotarget</i> , 2015, 6, 18162-18173.	0.8	90
39	Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.4	41
40	Noninvasive diagnostic methods for <i>Helicobacter pylori</i> infection. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 83-84.	0.6	3
41	The Primary Resistance of <i>Helicobacter pylori</i> in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factorsâ€”A Nationwide Study. <i>PLoS ONE</i> , 2015, 10, e0124199.	1.1	74
42	Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. <i>Gut</i> , 2015, 64, 1517-1528.	6.1	64
43	Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. <i>Journal of the Chinese Medical Association</i> , 2014, 77, 508-512.	0.6	22
44	Different Peptic Ulcer Bleeding Risk in Chronic Kidney Disease and End-Stage Renal Disease Patients Receiving Different Dialysis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 807-813.	1.1	38
45	Nonpeptic Ulcer, Nonvariceal Gastrointestinal Bleeding in Hemodialysis Patients. <i>American Journal of Medicine</i> , 2013, 126, 264.e25-264.e32.	0.6	42
46	Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. <i>Journal of the Chinese Medical Association</i> , 2013, 76, 9-14.	0.6	17
47	Risk of Hepato-Biliary Cancer After Cholecystectomy: a Nationwide Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 345-351.	0.9	19
48	Sequential versus triple therapy for the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2013, 381, 205-213.	6.3	233
49	Diabetes is an independent risk factor for peptic ulcer bleeding: A nationwide populationâ€based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1295-1299.	1.4	50
50	The Diminished Expression of Proangiogenic Growth Factors and Their Receptors in Gastric Ulcers of Cirrhotic Patients. <i>PLoS ONE</i> , 2013, 8, e61426.	1.1	2
51	Clopidogrel delays gastric ulcer healing in rats. <i>European Journal of Pharmacology</i> , 2012, 695, 112-119.	1.7	17
52	Concurrence of UGT1A Polymorphism and End-Stage Renal Disease Leads to Severe Toxicities of Irinotecan in a Patient with Metastatic Colon Cancer. <i>Tumori</i> , 2011, 97, 243-247.	0.6	8
53	Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. <i>Cmaj</i> , 2011, 183, E1345-E1351.	0.9	93
54	Omeprazole promotes gastric epithelial cell migration. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 655-660.	1.2	10

#	ARTICLE	IF	CITATIONS
55	Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. <i>Clinical Therapeutics</i> , 2010, 32, 1294-1303.	1.1	10
56	Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 756-761.	1.1	6
57	Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 252-259.	1.1	27
58	Gastroprotective Strategy in Aspirin Users. <i>Journal of the Chinese Medical Association</i> , 2009, 72, 343-345.	0.6	10
59	Dexamethasone Inhibits Tumor Necrosis Factor- α -stimulated Gastric Epithelial Cell Migration. <i>Journal of the Chinese Medical Association</i> , 2009, 72, 509-514.	0.6	8
60	Dexamethasone inhibits basic fibroblast growth factor-stimulated gastric epithelial cell proliferation. <i>Biochemical Pharmacology</i> , 2008, 76, 841-849.	2.0	31
61	Growth factors expression in patients with erosive esophagitis. <i>Translational Research</i> , 2008, 152, 81-87.	2.2	7
62	Dexamethasone Inhibits Epidermal Growth Factor-Stimulated Gastric Epithelial Cell Proliferation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 687-694.	1.3	23
63	Clinical significance of serum autoantibodies in Chinese patients with chronic hepatitis C: Negative role of serum viral titre and genotype. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 475-479.	1.4	32